Acute Gout Flare Market to Rise at a Significant CAGR | Dyve Biosciences, R-Pharm, Swedish Orphan Biovitrum, and others expected to boost the market

DelveInsight's "Acute Gout Flare - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Acute Gout Flare market share of the individual therapies, current and forecasted Acute Gout Flare market size from 2020 to 2034 segmented by seven major markets. The report also offers current Acute Gout Flare therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Gout Flare market.

Request for a Free Acute Gout Flare Market Sample Report @ https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the acute gout flare market report:

Acute gout flare, influenced by factors such as age, gender, and lifestyle, presents a significant global burden, adversely affecting patients' quality of life and driving up healthcare costs. Despite the increasing incidence, many cases remain underdiagnosed and undertreated, highlighting the urgent need for better awareness and management strategies to address these disparities and alleviate the overall impact on individuals and healthcare systems.

Gender-specific trends in acute gout flares reveal that males, particularly those who are middle-aged or older, experience higher rates. This difference is primarily linked to hormonal factors, as men typically have higher serum uric acid levels due to the effects of testosterone. Women are also at risk, especially post-menopause when estrogen levels decline.

The gout market is expected to expand positively, driven by the introduction of new therapies and the growing need for effective management of the condition. Key players in this space include Olatec Therapeutics and Dyve Biosciences, among others.

Significant growth is anticipated in the acute gout flare market, supported by a robust pipeline of innovative drug candidates globally. Emerging therapies, such as Interleukin (IL)-1 inhibitors (e.g., Dapansutrile) and DYV700, aim to address the unmet needs within this market.

Acute Gout Flare Overview
Acute gout flare is a sudden and intense episode of pain, swelling, and inflammation in the joints, most commonly affecting the big toe. Gout is a type of inflammatory arthritis caused by the accumulation of uric acid crystals in the joints, leading to painful flares. This condition can be recurrent and is often associated with lifestyle factors, dietary choices, and underlying health conditions.

Causes
The primary cause of an acute gout flare is the accumulation of uric acid in the blood, which can crystallize in the joints. Factors contributing to high uric acid levels include:

Diet: High purine foods (e.g., red meat, shellfish, sugary beverages) can increase uric acid levels.
Alcohol consumption: Especially beer and spirits, can elevate uric acid.
Obesity: Excess body weight can increase uric acid production and reduce its elimination.
Dehydration: Insufficient fluid intake can lead to higher concentrations of uric acid.
Medications: Certain diuretics and medications can raise uric acid levels.
Medical conditions: Conditions like kidney disease, hypertension, and metabolic syndrome can contribute to increased uric acid.
Signs and Symptoms
Symptoms of an acute gout flare typically include:

Intense Pain: Sudden onset of severe pain in the affected joint, often at night.
Swelling: Inflammation and swelling around the joint.
Redness and Warmth: The skin over the affected joint may appear red and feel warm to the touch.
Limited Range of Motion: Difficulty moving the affected joint due to pain and swelling.
Duration: The flare can last from a few days to several weeks if untreated.
Diagnosis
Diagnosis of acute gout is primarily clinical, based on symptoms and medical history, but may involve:

Physical Examination: Assessment of joint swelling, redness, and tenderness.

Joint Fluid Analysis: A sample of synovial fluid may be extracted from the affected joint and examined under a microscope for uric acid crystals.

Blood Tests: Measurement of uric acid levels, although high levels do not always confirm gout.

Imaging Studies: X-rays or ultrasound may be used to assess joint damage or the presence of crystals.

Treatment Options
Management of acute gout flares focuses on relieving pain and inflammation:

Medications:

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Such as ibuprofen or naproxen to reduce pain and inflammation.
Colchicine: Effective in reducing inflammation, particularly if taken early in the flare.
Corticosteroids: Such as prednisone, can be used for severe cases or when NSAIDs and colchicine are not suitable.
Lifestyle Modifications:

Dietary Changes: Avoiding high-purine foods, reducing alcohol intake, and increasing hydration.
Weight Management: Achieving and maintaining a healthy weight can lower uric acid levels.
Preventive Medications (for recurrent gout):

Urate-lowering therapy: Medications like allopurinol or febuxostat can help reduce uric acid levels over time.

Acute gout flares can be intensely painful and disruptive, but with proper diagnosis and treatment, symptoms can be effectively managed. Understanding the underlying causes and making lifestyle adjustments can help prevent future episodes. If you suspect you have gout, it's important to consult a healthcare professional for appropriate management.

Learn more about Acute Gout Flare, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Gout Flare Treatment Market:
Acute gout flare is marked by a sudden onset of joint pain, swelling, redness, and tenderness, often peaking within 24 hours. The first metatarsophalangeal joint is frequently affected. Clinical signs such as the presence of tophi and elevated serum uric acid levels can assist in diagnosis. Confirming the diagnosis relies on identifying monosodium urate crystals in joint fluid. Imaging techniques, including ultrasound and dual-energy CT, can further support the diagnosis. It's also important to consider differential diagnoses, such as septic arthritis. Prompt and accurate diagnosis is crucial for effective management of acute gout flares.

Treatment for acute gout attacks typically involves pharmacological options, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or COX-2 inhibitors, corticosteroids, colchicine, or local steroid injections. The goal of immediate therapy is to alleviate pain and promote a swift resolution of symptoms. For patients experiencing frequent flares and who have contraindications to conventional treatments, an Interleukin-1 blocker may be considered. As our understanding of disease mechanisms improves, new treatment approaches, including inflammatory inhibitors, are emerging as promising options.

Acute Gout Flare Epidemiology Insights
According to the analysis, the annual incidence of gout in the UK is 2.68 per 1,000 people. Men are more susceptible to gout than women, with prevalence rates of 3-6% for men and 1-2% for women in Western countries; in some regions, prevalence may rise to 10%. Recent reports indicate considerable variability in the prevalence and incidence of gout depending on the population studied and the methodologies used, ranging from a prevalence of less than 1% to 6.8% and an incidence of 0.58 to 2.89 per 1,000 person-years. Gout is more common in men and tends to increase with age, with both prevalence and incidence on the rise globally.

In the United States, gout affects approximately 9.2 million individuals, or about 3.9% of the adult population, with higher rates observed in men and older adults. In Germany, the standardized prevalence of gout is reported at 1.63%, translating to roughly 1.325 million affected individuals, while the standardized incidence rate is 0.45%. The male-to-female ratio for prevalence is 3.2:1, and for incidence, it is 2.7:1. The average age at diagnosis is estimated to be 66 years.

The incidence and prevalence of gout increase with age. The incidence per 100,000 people by age group is as follows: 18-29 years: 31; 30-39 years: 69; 40-49 years: 67; 50-59 years: 155; 60-69 years: 244; 70-79 years: 294; and 80 years and older: 367.

Explore more about Acute Gout Flare Epidemiology at: https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Gout Flare Treatment Market
Treatment for acute gout attacks typically starts with first-line options such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 inhibitors, anti-inflammatory corticosteroids, colchicine, or local steroid injections. The primary goal of immediate therapy is to alleviate pain and promote a swift resolution of symptoms. Often, acute attacks are followed by recurrent episodes with shorter intervals, potentially leading to chronic gout. Chronic gout is characterized by chronic synovitis, bone erosions, cartilage damage, and the formation of tophi.

The European League Against Rheumatism (EULAR) recommends IL-1 blockers for managing gout flares in patients with frequent episodes who cannot tolerate NSAIDs, colchicine, or steroids (oral or injectable). Canakinumab, a long-lasting IL-1 beta antibody, has been approved by the European Medicines Agency following two randomized controlled trials comparing it to intramuscular triamcinolone acetonide. Additionally, Anakinra, an IL-1 receptor antagonist, is used off-label in similar cases. Urate-lowering drugs (ULDs) are also prescribed to help manage blood uric acid levels.

In August 2023, the FDA expanded the approval of ILARIS (canakinumab) to include the treatment of gout flares in adults. This approval applies to patients who cannot take NSAIDs or colchicine, who do not respond adequately to these treatments, and for whom repeated courses of corticosteroids are not appropriate.

With ongoing research and development of various marketed IL-1 blockers for treating and managing gout flares, the acute gout flare market is expected to undergo significant changes during the study period, given their established safety and side-effect profiles.

According to DelveInsight, the acute gout flare market across the seven major markets (7MM) is projected to experience considerable transformation from 2024 to 2034.

Request a sample and discover more about the Acute Gout Flare Market report offerings at: https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Promising Therapies in the Acute Gout Flare Pipeline
● DYV700
● RPH - 104
● Anakinra
● And others

Request for a sample report to understand more about the Acute Gout Flare pipeline development activities at: https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Acute Gout Flare Market
● Dyve Biosciences, Inc.
● R-Pharm
● Swedish Orphan Biovitrum
● And others
Acute Gout Flare Drug Chapters
Acute Gout Flare Marketed Drugs

ILARIS (canakinumab): NOVARTIS PHARMS
ILARIS, an interleukin-1 receptor antagonist, presents a promising strategy for managing acute gout flares. By blocking the action of interleukin-1, a crucial inflammatory mediator in gout, ILARIS helps alleviate pain and inflammation during acute attacks. This medication serves as an effective alternative for patients who may not respond adequately to traditional treatments like nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine. Furthermore, ILARIS has demonstrated potential in preventing recurrent gout flares, providing a comprehensive treatment option for individuals suffering from gout.

Emerging Acute Gout Flare Drugs
OLT1177 (Dapansutrile): Olatec Therapeutics

This investigational small molecule is a new chemical entity that specifically targets and inhibits NLRP3 (nucleotide-binding and oligomerization domain [NOD]-, leucine-rich repeat-, pyrin domain-containing 3), a key sensor molecule involved in the formation of the NLRP3 inflammasome. Currently, it is in Phase II/III clinical trials and has shown good tolerance among patients while improving clinical outcomes in those experiencing acute gout flares. The company has reported positive results from the Phase IIa trial (Study OLT1177-05). This molecule is notable as the first selective NLRP3 inhibitor to demonstrate clinical benefits, safety, and a reduction in systemic inflammation.

DYV700: Dyve Biosciences

DYV700 is Dyve's innovative therapeutic developed using their proprietary skin penetration platform technology. In 2022, Dyve reached a significant milestone with the successful completion of a Phase II study, demonstrating the efficacy of DYV700 in alleviating pain associated with the acidic microenvironment of acute gouty arthritis. This breakthrough was supported by biomarker data, confirming the effectiveness of transdermal pH modulation in addressing the acidic conditions of the disease. The potential of DYV700 offers hope to millions of gout patients suffering from the severe pain of acute flares. Given the limited advancements in acute gout treatments and the slow onset and side effects of current options, the promising results from DYV700's pilot study suggest a transformative change in the management of acute gout may be on the horizon.

To understand key companies related to the Acute Gout Flare Market, get a snapshot of the Acute Gout Flare Regulatory and Patent Analysis @ https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Acute Gout Flare Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Acute Gout Flare Companies: Dyve Biosciences, Inc., R-Pharm, Swedish Orphan Biovitrum, and others.
Key Acute Gout Flare Pipeline Therapies: DYV700, RPH - 104, Anakinra, and others
Therapeutic Assessment: Acute Gout Flare current marketed and emerging therapies
Acute Gout Flare Market Dynamics: Acute Gout Flare market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute Gout Flare Market Access and Reimbursement
Table of Contents
1. Acute Gout Flare Market Key Insights
2. Acute Gout Flare Market Report Introduction
3. Acute Gout Flare Market Overview at a Glance
4. Acute Gout Flare Market Executive Summary
5. Disease Background and Overview
6. Acute Gout Flare Treatment and Management
7. Acute Gout Flare Epidemiology and Patient Population
8. Patient Journey
9. Acute Gout Flare Emerging Drugs
10. 7MM Acute Gout Flare Market Analysis
11. Acute Gout Flare Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Acute Gout Flare Market Drivers
15. Acute Gout Flare Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us
Name: Kritika Rehani
E-mail: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.